


Corporate Presentation

July 11, 2019



ENANTA
Pharmaceuticals

Creating Small Molecule Drugs for Viral Infections and Liver Diseases

Forward Looking Statements Disclaimer

This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business prospects and the industry in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, as well as other comparable terminology. All are forward-looking statements based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. These risks and uncertainties include the following: (i) our financial prospects for the next several years are dependent upon the development and commercializing efforts of AbbVie for combination therapies for HCV incorporating paritaprevir, or glecaprevir, (ii) competition for these therapies, and (iii) the length, uncertainty and expense of discovering and developing new therapeutics for other diseases. As a result, any or all of our forward-looking statements in this presentation may turn out to be inaccurate.


Please refer to these and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Form 10-K, and other periodic reports filed with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this presentation. These statements speak only as of the date of this presentation, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

Investment Highlights

- Virology & liver disease-focused biotech company
- Two partnered products marketed in AbbVie's HCV regimens:
 - Glecaprevir – HCV protease inhibitor in MAVYRET™/MAVIRET™
 - Paritaprevir – HCV protease inhibitor in VIEKIRA* regimens
 - Fiscal 2Q19 royalties on HCV regimens: \$39.6 million
- Four clinical-stage programs in areas of high unmet medical need:
 - RSV: Phase 2a human challenge study complete
 - NASH: Phase 2 “ARGON-1” study ongoing
 - PBC: Phase 2 “INTREPID” study ongoing
 - HBV: Phase 1 study ongoing
- Ongoing R&D programs in NASH/PBC, HBV and RSV
- Strong balance sheet to fund clinical programs and other R&D efforts
 - Approx. \$386.7M in cash at 3/31/19

Our Therapeutic Focus

- Leverage our core strength in HCV to become a leader in **Viral** and **Liver** diseases
- Multiple new therapeutic areas with goal of building multiple approaches in each




Broad Virology and Liver Disease Pipeline

Product Candidate		Discovery	Preclin	Phase 1	Phase 2	Phase 3	Market
HCV	Protease Inhibitor	glecaprevir – containing pan-genotypic 2-DAA combo					
HCV	Protease Inhibitor	paritaprevir – containing regimens					
RSV	N-protein Inhibitor	EDP-938	Ph 2 Challenge Study				
NASH	FXR Agonist	EDP-305	Ph 2 “ARGON-1”				
PBC	FXR Agonist	EDP-305	Ph 2 “INTREPID”				
HBV	Core Inhibitor	EDP-514	Ph 1				
NASH	FXR Agonist Follow-on						
NASH	Undisclosed						

Glecaprevir – A Pan-genotypic HCV Protease Inhibitor


- Glecaprevir: the protease inhibitor in AbbVie's MAVYRET™*
 - RBV-free, once-daily, fixed-dose combination (2-DAA)
 - MAVYRET treats the majority of patients today in only 8-weeks
- Also treats patients with specific challenges:
 - compensated cirrhosis
 - severe chronic kidney disease
 - PI or NS5A treatment failures
- Marketed by AbbVie (U.S., EU, Japan & other countries globally)
- Market for HCV therapies: ~ \$8 billion in 2018

MAVYRET™
glecaprevir/pibrentasvir
100 mg/40 mg tablets




Glecaprevir– The Pan-genotypic HCV Protease Inhibitor in AbbVie's MAVYRET™

Product	Regimen	Enanta Asset	Economics*
 glecaprevir/pibrentasvir 100 mg/40 mg tablets	2-DAA (ABBV)	glecaprevir (PI)	Double-digit royalty on 50% of net sales



Virology & Liver Disease Focus Areas



Respiratory Syncytial Virus (RSV)

- Negative-sense, single-stranded RNA virus of family Pneumoviridae
- Can cause severe lung infections, including bronchiolitis (infection of small airways in the lungs) and pneumonia (an infection of the lungs)
- Higher risk populations for severe illness include:
 - Premature babies
 - Older adults, especially those 65 years and older
 - People with chronic lung disease or certain heart problems
 - People with weakened immune systems (e.g. HIV, organ transplant, chemotherapy)
- Each year in U.S.:
 - > 57,000 children below age 5 are hospitalized for RSV
 - ~ 177,000 older adults are hospitalized, and about 14,000 die
- No safe and effective treatments


Source: CDC

EDP-938: Enanta's First Clinical-Stage Compound for RSV

- EDP-938 is the only N-inhibitor under clinical evaluation
 - Non-Fusion approach directly targets viral replication
- Strong preclinical virological profile:
 - Nanomolar inhibitor of both RSV-A and RSV-B activity
 - Maintained antiviral potency across all clinical isolates tested
 - Demonstrated high-barrier to resistance *in vitro*
 - Synergy with other drug mechanisms (e.g. fusion and L inhibitors)
 - Active against resistant virus from other mechanisms
 - Robust *in vivo* efficacy data
- Phase 2a human challenge study complete

Phase 2a Challenge Study (EDP 938-101)

Study Design and Procedures




** Dosing (D0) is initiated 12 hours after testing positive for RSV or Day 5 (PM), whichever comes first

\$ EDP-938/placebo is administered as a blinded oral liquid suspension

- EDP-938 500mg loading dose, then 300mg BID over 5 days
- EDP-938 600mg QD Q24h alternating with placebo Q24h x 5 days to maintain the blind
- Placebo for EDP-938 BID x 5 days

Robust Antiviral Effect

Rapid and Sustained Reduction in Viral Load in Both Active Arms Compared to Placebo



Dosing Period

First Dose


Highly Statistically Significant Reduction in Both EDP-938 Arms Compared to Placebo

- No Statistically Significant Difference Between the Two Dosing Regimens

	EDP-938 600 mg QD	EDP-938 500 mg LD + 300 mg BID	Placebo
N	25	31	30
Viral load AUC mean (SD) (hours x Log ₁₀ copies/mL)	203.95 (173.50)	217.71 (217.55)	790.15 (408.80)
% Reduction (relative to placebo)	74.43%	71.46%	
Absolute Reduction* (relative to placebo)	-588.08	-564.63	
P-value	<0.001	<0.001	
Difference between two EDP-938 dosing groups	-23.45		
P-value	0.722		

* Difference in LS Mean

EDP-938 Shows a Rapid and Sustained Attenuation of RSV Symptoms Compared to Placebo



Dosing Period

First Dose

Both EDP-938 Regimens Demonstrated Highly Statistically Significant Attenuation of RSV Symptoms Compared to Placebo

- No Statistically Significant Difference Between the Two Dosing Regimens


	EDP-938 600 mg QD	EDP-938 500 mg LD/300 mg BID	Placebo
N	25	31	30
AUC Total Symptom Score mean (SD) (hours x Score)	124.47 (115.60)	181.75 (248.42)	478.75 (422.29)
% Reduction (relative to placebo)	74.3%	68.2%	
Absolute Reduction* (relative to placebo)	-355.91	-326.64	
P-value	<0.001	<0.001	
Difference between two EDP-938 dosing groups	-29.27		
P-value	0.700		

* Difference in LS Mean

Summary: EDP-938, A Highly Efficacious and Safe RSV N-Inhibitor

- Phase 1 results:
 - Safe and well tolerated, no SAEs, AEs were mild
 - At Phase 2 doses, mean trough levels 30x higher than EC 90 of EDP-938 against RSV-infected human cells
- Phase 2a Results:
 - Primary and Key Secondary Efficacy Endpoints were achieved ($p < 0.001$) at both dose levels after 5 days of dosing
 - EDP-938 mean C_{trough} concentrations were approximately >20-40x higher than EC_{90}
 - Well tolerated with safety profiles similar to placebo (consistent profile observed in >250 subjects exposed to EDP-938 for up to 7 days in Phase 1 and Phase 2a)
- Future Phase 2 studies will focus on both adult and infant populations


Virology & Liver Disease Focus Areas



Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)

- Number one cause of liver disease in Western Countries
- NAFLD: **excessive fat (triglyceride)** accumulation in the liver (steatosis)
- A subgroup of NAFLD patients has **liver cell injury and inflammation** in addition to **excessive fat** (steatohepatitis), *i.e.* NASH
- NASH is associated with the metabolic syndrome – diseases related to type 2 diabetes, insulin resistance, obesity, hyperlipidemia, and hypertension
- While NAFLD does not correlate with short-term morbidity or mortality, but progression to NASH dramatically increases risks of cirrhosis, liver failure, and hepatocellular carcinoma

Stages of
Liver Injury
(NIDDK)



Enanta's Approach to NASH and PBC– Agonists of Farnesoid X Receptor (FXR)


- FXR

- nuclear receptor
- main regulator of bile acid levels in liver and small intestine
- responds to bile acids by regulating transcription of key enzymes and transporters

- FXR agonist preclinical PoC


- ameliorate pathologies in NASH and PBC models, including an effect on fibrosis

- Clinical validation of FXR agonist in NASH and PBC with 6-ECDCA (OCA)




Classification of FXR Agonists – Four fundamental types (with variations)

Steroidal




Linker




carboxylic acid
non-carboxylic acid

Non-steroidal



Linker



carboxylic acid
non-carboxylic acid

FXR Agonists		Example
Steroidal carboxylic acid	S-CA	OCA, bile acids
Steroidal non-carboxylic acid	S-NCA	Enanta compounds
Non-steroidal carboxylic acid	NS-CA	Enanta compounds, GS-9674, LNJ452
Non-steroidal non-carboxylic acid	NS-NCA	Enanta compounds

FXR Agonist EDP-305: Introduction

- EDP-305: **Steroidal non-carboxylic acid**, modified with additional **non-steroidal** binding element to enhance potency
- Potent FXR receptor agonist activity vs OCA
- Highly selective for FXR vs other nuclear receptors
 - and vs TGR5 receptor
- Potent and differentiated effects on FXR-dependent gene expression vs OCA
 - e.g. Shp, Cyp7a1, Bsep, Fgf15/FGF19
 - human hepatocytes and *in vivo* mouse model
- Efficacy in multiple NASH models
 - STAMTM mouse NASH model and dietary-induced NASH (DIN) mouse model
 - Improvement in hepatocyte ballooning and overall NAFLD Activity Score vs OCA
- Reduced liver fibrosis in rodent models
 - Mdr2^{-/-}, MCD, CDAHFD, thioacetamide, and bile duct ligation models


EDP-305 Phase 1 Study

- Double-blind, placebo-controlled, Phase 1a/b study
- Healthy adults, and adults with presumptive NAFLD (“PN”)
 - PN were obese, with or without pre-diabetes or type 2 diabetes mellitus, mean BMI= 32
- Oral suspension EDP-305 or placebo, dosed once daily
 - Total N=146 subjects (n=110 EDP305, n=36 pbo)
 - SAD, n=50, 6 cohorts at 1, 5, 10, 20, 40 and 80 mg
 - MAD, n=48 healthy and n=48 PN, 6 cohorts at 0.5, 1, 2.5, 5, 10, and 20 mg for 14 days
- Safety, tolerability, PK, and proof of target engagement support progression to Phase 2 with once daily dosing

FXR Agonist EDP-305: Phase 2 Studies

- Fast Track Designation granted by FDA for PBC and for NASH with fibrosis
- Two Phase 2 studies ongoing:
 - “ARGON-1” (NASH) and “INTREPID” (PBC)
 - 12 week dose ranging, randomized, double-blind, placebo-controlled
 - Evaluate safety, tolerability, PK, and efficacy (ALP reduction in PBC and ALT reduction in NASH)
 - New tablet formulation at 1 and 2.5 mg (~2X greater exposure than Phase 1 suspension formulation)
 - ARGON-1 enrollment complete

Virology & Liver Disease Focus Areas



HBV Background

- Potentially life-threatening liver infection caused by the hepatitis B virus
- Current treatments rarely give true cures
 - **Interferon** gives better results (~10%), but with side effects
 - **RT inhibitors** very effective at reducing viral load, but offer very low cure rates (1% or lower) and must be taken for life to improve cirrhosis or HCC outcomes
- Prevalence estimates
 - US: ~850,000 - 2 million
 - US + Japan + major EU populations: ~4.9 million
 - Worldwide: ~250 million
- Estimated 15-25% of patients with chronic HBV infection will develop chronic liver diseases including cirrhosis, HCC, or liver decompensation




Core inhibitors: Introduction


(also called capsid assembly modulators, core protein allosteric modulators, capsid inhibitors)

- Novel class of replication inhibitor
- Act at multiple steps in HBV lifecycle
 - prevent proper uncoating, nuclear import, assembly, and recycling


Phenylpropenimides
(AT-130)





HAPs
(GLS4)



Sulfamoylbenzamides
(SBA-R01)



Isothiafludine
(NZ-4)



Core Inhibitor EDP-514 is a Potent Inhibitor of HBV Replication

- EDP-514 is active in multiple HBV stable cell lines

	HBV Stable Cell Line EC ₅₀ (nM)		
	HepAD38	HepDE19	HepG2.2.15
Intracellular Viral DNA	18	27	17
Encapsidated pgRNA	25	3	5
HBeAg	20	34	>500*

* In HepG2.2.15 cells, HBeAg is transcribed off transgene and is not dependent on viral replication

Viral DNA measured by qPCR

Encapsidated pgRNA measured by modified pulldown and qPCR

HBeAg measured by commercial ELISA kit


EDP-514 Prevents *de novo* Formation of cccDNA in Primary Human Hepatocytes

- EDP-514 prevents cccDNA establishment when present at early time points in infection (HBsAg as surrogate marker)

Compound	HBsAg EC ₅₀ (nM)		HBV DNA EC ₅₀ (nM)	
	d0 Addition	d3 Addition	d0 Addition	d3 Addition
EDP-514	35	>1000	10	6
Entecavir	>1000	>1000	0.25	0.21

EDP-514 is Efficacious in the Humanized Liver Mouse Model

- uPA/SCID mice were infected with genotype C HBV and subsequently treated with EDP-514 BID at indicated doses for 12 weeks



HBV Core Inhibitor EDP-514 Summary


- A novel core inhibitor that displays potent anti-HBV activity at multiple points in the HBV lifecycle
- *In vitro*:
 - Potent anti-HBV activity in HBV expressing stable cells lines
 - Capable of preventing the establishment of cccDNA
 - Potent pan-genotypic activity
- *In vivo*:
 - Favorable tolerability and pharmacokinetic profile
 - Over 4-log reduction in HBV viral titers with 12 weeks of treatment in a chimeric liver mouse model
- Fast Track designation by FDA
- Phase 1 ongoing

Financial Highlights

(\$ In millions)	Fiscal Year Ended Sept. 30, 2018	Fiscal 2Q19
Total Revenues	206.6*	\$39.6
R&D Expenses	\$94.9	\$34.2
G&A Expenses	\$23.4	\$6.8
Net Income	\$71.9	\$4.1
EPS (per diluted share)	\$3.48	\$0.20
Balance Sheet		
Cash, Cash Equivalents and Marketable Securities	\$325.1	\$386.7

* Includes \$15M milestone payment from AbbVie for reimbursement approval of MAVIRET™ in Japan

Key Catalysts



- Ongoing double-digit HCV royalties from glecaprevir (MAVYRET™)
- RSV program:
 - Goal – Initiate Phase 2b adult outpatient study by end of 2019
- FXR agonist EDP-305 for NASH / PBC:
 - Phase 2 data in NASH by end of 3Q19
 - Identify follow-on FXR clinical candidate for NASH in 2019
 - Advance non-FXR compounds for NASH
 - Continued PBC enrollment in 2019
- HBV program:
 - Continue Phase 1 with Core Inhibitor EDP-514

ENANTA

Pharmaceuticals

Creating Small Molecule Drugs for Viral Infections and Liver Diseases
www.enanta.com

